XOMA Corp (XOMA) Stock Rating Lowered by Wedbush
XOMA Corp (NASDAQ:XOMA) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday. They presently have a $14.00 target price on the stock, down from their prior target price of $17.00. Wedbush’s price target points to a potential upside of 91.00% from the company’s previous close.
Several other brokerages have also issued reports on XOMA. Cowen and Company reissued a “market perform” rating on shares of XOMA Corp in a research note on Thursday, November 10th. Zacks Investment Research raised XOMA Corp from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Wednesday, October 26th. Finally, Jefferies Group reissued a “hold” rating on shares of XOMA Corp in a research note on Friday, August 5th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.33.
XOMA Corp (NASDAQ:XOMA) opened at 7.33 on Monday. The company has a market capitalization of $44.19 million, a PE ratio of 32.43 and a beta of 3.71. The firm’s 50-day moving average is $3.49 and its 200-day moving average is $1.36. XOMA Corp has a 52-week low of $4.70 and a 52-week high of $7.46.
XOMA Corp (NASDAQ:XOMA) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($2.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.40) by $0.32. The business earned $0.64 million during the quarter, compared to analyst estimates of $1.29 million. XOMA Corp’s revenue was down 69.1% compared to the same quarter last year. On average, equities research analysts forecast that XOMA Corp will post ($9.07) EPS for the current year.
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of XOMA Corp by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock worth $2,934,000 after buying an additional 871,594 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of XOMA Corp during the first quarter worth $374,000. Wedbush Securities Inc. raised its position in shares of XOMA Corp by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock worth $223,000 after buying an additional 15,827 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of XOMA Corp during the second quarter worth $185,000. Finally, Bellevue Group AG purchased a new position in shares of XOMA Corp during the first quarter worth $174,000.
XOMA Corp Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Stock Ratings for XOMA Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corp and related stocks with our FREE daily email newsletter.